About Synaptotagmin-11
Synaptotagmin-11 (SYT11) is a protein
from Homo sapiens identified by UniProt accession
Q9BT88, 431 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Synaptotagmin-11 |
|---|
| UniProt accession | Q9BT88 |
|---|
| Gene | SYT11 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 431 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- sex hormone-binding globulin measurement · score 0.20
- lung adenocarcinoma · score 0.18
- Immature Reticulocyte Fraction Measurement · score 0.15
- body mass index · score 0.10
- vitamin D measurement · score 0.08
- gonorrhea · score 0.07
- blood protein measurement · score 0.07
- body weight · score 0.07
- gastric carcinoma · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BT88-F1 | alphafold | PREDICTED | 75.51 | — |
Amino-acid sequence (431 residues)
MAEITNIRPS FDVSPVVAGL IGASVLVVCV SVTVFVWSCC HQQAEKKQKN PPYKFIHMLK GISIYPETLS NKKKIIKVRR DKDGPGREGG RRNLLVDAAE AGLLSRDKDP RGPSSGSCID QLPIKMDYGE ELRSPITSLT PGESKTTSPS SPEEDVMLGS LTFSVDYNFP KKALVVTIQE AHGLPVMDDQ TQGSDPYIKM TILPDKRHRV KTRVLRKTLD PVFDETFTFY GIPYSQLQDL VLHFLVLSFD RFSRDDVIGE VMVPLAGVDP STGKVQLTRD IIKRNIQKCI SRGELQVSLS YQPVAQRMTV VVLKARHLPK MDITGLSGNP YVKVNVYYGR KRIAKKKTHV KKCTLNPIFN ESFIYDIPTD LLPDISIEFL VIDFDRTTKN EVVGRLILGA HSVTASGAEH WREVCESPRK PVAKWHSLSE Y
Explore Synaptotagmin-11 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets